Sugi Predict

Sugi Predict / Compounds / SCHEMBL5519562

SCHEMBL5519562

SCHEMBL5519562

COc1ccc(Cn2nnc(C(=O)c3cc(OC)c(OC)cc3[N+](=O)[O-])c2C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ KDM4E B2RXH2 5/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ AKR1C3 P42330 5/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7827135 0.94 POLB (0.43) LMNACASP3SENP8SENP7SENP6
SCHEMBL5514056 0.92 LMNA (0.46) LMNACASP3SENP8SENP7SENP6
SCHEMBL7827738 0.90 ALOX15 (0.42) POLBMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL5513825 0.89 UCHL1 (0.45) LMNACASP3SENP8SENP7SENP6
SCHEMBL7827258 0.88 ALOX15 (0.42) POLBMAPTALDH1A1KDM4ENPC1
SCHEMBL7815954 0.87 HPGD (0.50) LMNAMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL7824446 0.87 SMN1; SMN2 (0.41) LMNAPOLBMAPTSMN1; SMN2NPC1
SCHEMBL7827810 0.86 ALOX15 (0.39) POLBMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL7816277 0.86 POLB (0.43) LMNACASP3SENP8SENP7SENP6
SCHEMBL7826324 0.85 MAPT (0.43) LMNAPOLBMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100387580-C Tricyclic triazolobenzazepine * derivatives, process for preparing the same, and antiallergic agent MEIJI SEIKA KAISHA (JP) 2008-05-14 — — CN disclosed
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 — — US disclosed
CN-1312135-C Tricyclic triazolobenzazepine * derivatives, process for preparing the same, and antiallergic agent MEIJI SEIKA KAISHA (JP) 2007-04-25 — — CN disclosed
CN-1781913-A Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agent MEIJI SEIKA KAISHA (JP) 2006-06-07 — — CN disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 — — US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 — — US disclosed
CN-1523019-A Tricyclic triazolobenzazepine * derivatives, process for preparing the same, and antiallergic agent �����Ƹ���ʽ���� 2004-08-25 — — CN disclosed
CN-1155599-C Tricyclic triazolobenzazepine * derivatives, process for preparing the same, and antiallergic agent �����Ƹ���ʽ���� 2004-06-30 — — CN disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 — — EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 — — US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 — — US disclosed
EP-0686636-B1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA CO (JP) 2001-04-04 — — EP disclosed
CN-1278262-A Tricyclic triazolobenzazepine * derivatives, process for preparing the same, and antiallergic agent MEIJI SEIKA KAISHA (JP) 2000-12-27 — — CN disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 — — EP disclosed
US-5840895-A INTERMEDIATES FOR ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1998-11-24 — — US disclosed
US-5686442-A ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1997-11-11 — — US disclosed
EP-0686636-A1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA KABUSHIKI KAISHA (JP) 1995-12-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 LMNA 3995/4885CASP3 791/4885SENP8 2518/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 LMNA 3991/4885CASP3 614/4885SENP8 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.